News articles about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.5283142675977 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.02 during mid-day trading on Thursday, reaching $6.24. The company had a trading volume of 256,900 shares, compared to its average volume of 430,391. The firm has a market cap of $321.86, a price-to-earnings ratio of -2.18 and a beta of 2.51. Tetraphase Pharmaceuticals has a twelve month low of $3.57 and a twelve month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.58) EPS. sell-side analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.
Several analysts recently commented on TTPH shares. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research note on Saturday, September 23rd. HC Wainwright boosted their price target on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, November 6th. BMO Capital Markets boosted their price target on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. Finally, ValuEngine lowered Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $15.15.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage acquired 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the purchase, the director now owns 38,880 shares in the company, valued at $250,776. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the transaction, the insider now directly owns 8,750 shares in the company, valued at approximately $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/18/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-tetraphase-pharmaceuticals-ttph-share-price.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.